Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. Fiskus W, et al. Among authors: birdwell c. Leukemia. 2021 Sep;35(9):2621-2634. doi: 10.1038/s41375-021-01181-w. Epub 2021 Mar 2. Leukemia. 2021. PMID: 33654205 Free PMC article.
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Fiskus W, et al. Among authors: birdwell c. Blood Cancer J. 2021 May 20;11(5):98. doi: 10.1038/s41408-021-00487-3. Blood Cancer J. 2021. PMID: 34016956 Free PMC article.
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Fiskus W, et al. Among authors: birdwell ce. Leukemia. 2022 Nov;36(11):2729-2733. doi: 10.1038/s41375-022-01707-w. Epub 2022 Sep 23. Leukemia. 2022. PMID: 36151141 Free PMC article. No abstract available.
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Mill CP, et al. Among authors: birdwell ce. Leukemia. 2023 Jun;37(6):1336-1348. doi: 10.1038/s41375-023-01882-4. Epub 2023 Mar 28. Leukemia. 2023. PMID: 36977823 Free PMC article.
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Fiskus W, et al. Among authors: birdwell c. Blood Cancer J. 2023 Apr 13;13(1):53. doi: 10.1038/s41408-023-00826-6. Blood Cancer J. 2023. PMID: 37055414 Free PMC article.
53 results